Literature DB >> 10618073

In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses.

J Piret1, J Lamontagne, J Bestman-Smith, S Roy, P Gourde, A Désormeaux, R F Omar, J Juhász, M G Bergeron.   

Abstract

The efficacy of sodium lauryl sulfate (SLS), a sulfated anionic chaotropic surfactant, and dextran sulfate (DS), a polysulfated carbohydrate, against herpes simplex virus (HSV) and human immunodeficiency virus (HIV) infections was evaluated in cultured cells and in different murine models of HSV infection. Results showed that both SLS and DS were potent inhibitors of the infectivities of various HSV-1 and HSV-2 strains. Pretreatment of HIV-1 (strain NL4-3) with SLS also reduced its infectivity to 1G5 cells. DS prevented the binding of HSV to cell surface receptors and therefore its entry into cells. Pretreatment of HSV-1 (strain F) with 50 microM SLS resulted in a complete loss of virus infectivity to Vero cells. However, viruses were able to enter into cells and to produce in the nuclei capsid shells devoid of a DNA core. The amount of the glycoprotein D gene produced in these cells remained unchanged compared to controls, suggesting that SLS could interfere with the maturation of the virus. At a higher SLS concentration (100 microM), HSV was highly damaged by SLS pretreatment and only a few viral particles could enter into cells to produce abnormal capsids. Although DS was a more potent inhibitor of HSV infectivity in vitro, it was unable to provide any protection in murine models of HSV infection. However, SLS conferred a complete protection of animals infected cutaneously with pretreated viruses. In addition, skin pretreatment of mice with a polymer formulation containing SLS completely prevented the development of cutaneous lesions. More interestingly, intravaginal pretreatment of mice with SLS in a buffered solution also completely protected against lethal HSV-2 infection. Taken together, our results suggest that SLS could thus represent a candidate of choice as a microbicide to prevent the sexual transmission of HIV, HSV, and possibly other pathogens that cause sexually transmitted diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618073      PMCID: PMC86033          DOI: 10.1128/JCM.38.1.110-119.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Characterization of three species of nucleocapsids of equine herpesvirus type-1 (EHV-1).

Authors:  M L Perdue; J C Cohen; M C Kemp; C C Randall; D J O'Callaghan
Journal:  Virology       Date:  1975-03       Impact factor: 3.616

2.  Biochemical studies of the maturation of herpesvirus nucleocapsid species.

Authors:  M L Perdue; J C Cohen; C C Randall; D J O'Callaghan
Journal:  Virology       Date:  1976-10-01       Impact factor: 3.616

Review 3.  Global epidemiology of sexually transmitted diseases.

Authors:  A C Gerbase; J T Rowley; T E Mertens
Journal:  Lancet       Date:  1998       Impact factor: 79.321

4.  Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro.

Authors:  M Ito; M Baba; A Sato; R Pauwels; E De Clercq; S Shigeta
Journal:  Antiviral Res       Date:  1987-07       Impact factor: 5.970

5.  Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2.

Authors:  W Gibson; B Roizman
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

6.  The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides.

Authors:  D Batinić; F A Robey
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

7.  Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens.

Authors:  B C Herold; A Siston; J Bremer; R Kirkpatrick; G Wilbanks; P Fugedi; C Peto; M Cooper
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity.

Authors:  J Neyts; E De Clercq
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-09-01

9.  Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes.

Authors:  J Kreiss; E Ngugi; K Holmes; J Ndinya-Achola; P Waiyaki; P L Roberts; I Ruminjo; R Sajabi; J Kimata; T R Fleming
Journal:  JAMA       Date:  1992 Jul 22-29       Impact factor: 56.272

10.  Comparative in vitro study of contraceptive agents with anti-HIV activity: gramicidin, nonoxynol-9, and gossypol.

Authors:  A S Bourinbaiar; S Lee-Huang
Journal:  Contraception       Date:  1994-02       Impact factor: 3.375

View more
  26 in total

1.  Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases.

Authors:  S Roy; P Gourde; J Piret; A Désormeaux; J Lamontagne; C Haineault; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Critical design features of phenyl carboxylate-containing polymer microbicides.

Authors:  Robert F Rando; Sakae Obara; Mark C Osterling; Marie Mankowski; Shendra R Miller; Mary L Ferguson; Fred C Krebs; Brian Wigdahl; Mohamed Labib; Hiroyasu Kokubo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  The Apical Region of the Herpes Simplex Virus Major Capsid Protein Promotes Capsid Maturation.

Authors:  Laura L Ruhge; Alexis G E Huet; James F Conway; Gregory A Smith
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

4.  Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.

Authors:  J Piret; J Lamontagne; A Désormeaux; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment.

Authors:  J Bestman-Smith; J Piret; A Désormeaux; M J Tremblay; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.

Authors:  F C Krebs; S R Miller; B J Catalone; P A Welsh; D Malamud; M K Howett; B Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

8.  A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.

Authors:  Dimitrios Motakis; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections.

Authors:  Valence M K Ndesendo; Viness Pillay; Yahya E Choonara; Eckhart Buchmann; David N Bayever; Leith C R Meyer
Journal:  AAPS PharmSciTech       Date:  2008-04-02       Impact factor: 3.246

10.  In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.

Authors:  F T G S Cardozo; I V Larsen; E V Carballo; G Jose; R A Stern; R C Brummel; C M Camelini; M J Rossi; C M O Simões; C R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.